Name: Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine: 2 (Human Perspectives in Health Sciences and Technology) (en Inglés)
SKU: 53859041
Price: 2516.41 MXN
Availability: InStock
Author: Bizzarri, Mariano
ISBN: 9783030328597

portada Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine: 2 (Human Perspectives in Health Sciences and Technology) (en Inglés)

Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine: 2 (Human Perspectives in Health Sciences and Technology) (en Inglés)

Formato

Libro Físico

Ilustrado por

Mariano Bizzarri

Editorial

Springer

Autor

Bizzarri, Mariano

Año

2021

Idioma

Inglés

N° páginas

483

Encuadernación

Tapa Blanda

Dimensiones

23.4x19.6x2.3 cm

Peso

0.82 kg.

ISBN13

9783030328597

N° edición

Categorías

Oncología
Farmacología
Biología, ciencias de la vida

Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine: 2 (Human Perspectives in Health Sciences and Technology) (en Inglés)

Mariano Bizzarri (Ilustrado por) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 17 a 22 días háb.

$ 5,032.83$ 2,516.41

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 2,516.41

¡Envío Gratis! Llega entre el 25 Sep y el 05 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine: 2 (Human Perspectives in Health Sciences and Technology) (en Inglés)"

This volume - for pharmacologists, systems biologists, philosophers and historians of medicine - points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.